Q Genetics
Quregenetics is a research-focused venture company specializing in developing first-in-class and best-in-class innovative drugs for metabolic diseases such as osteoporosis, fractures, and sarcopenia in the aging population. Leveraging mesenchymal stem cell differentiation technology, big data, and artificial intelligence, they have invented a small molecule synthetic new drug, QG3030, targeting metabolic-related indications. Their business model revolves around biotechnology, focusing on the discovery and development of innovative treatments for diseases like osteoporosis, fractures, sarcopenia, and obesity. They also develop a platform and therapeutics for infectious diseases, particularly for ssRNA viruses, by providing a cell-based screening platform to pharmaceutical companies. The company's philosophy centers on improving quality of life through endless questions and continuous exploration, aiming to provide confidence to patients and contribute to society.
Q Genetics
Quregenetics is a research-focused venture company specializing in developing first-in-class and best-in-class innovative drugs for metabolic diseases such as osteoporosis, fractures, and sarcopenia in the aging population. Leveraging mesenchymal stem cell differentiation technology, big data, and artificial intelligence, they have invented a small molecule synthetic new drug, QG3030, targeting metabolic-related indications. Their business model revolves around biotechnology, focusing on the discovery and development of innovative treatments for diseases like osteoporosis, fractures, sarcopenia, and obesity. They also develop a platform and therapeutics for infectious diseases, particularly for ssRNA viruses, by providing a cell-based screening platform to pharmaceutical companies. The company's philosophy centers on improving quality of life through endless questions and continuous exploration, aiming to provide confidence to patients and contribute to society.